市场调查报告书
商品编码
1466118
血浆蛋白治疗市场:依产品、应用分类 - 2024-2030 年全球预测Plasma Protein Therapeutics Market by Product (Albumins, C1-esterase Inhibitors, Coagulation Factors), Application (Hereditary Angioedema, Idiopathic Thrombocytopenic Purpura, Primary Immunodeficiency Disorder) - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
血浆蛋白治疗市场规模预计2023年为325.5亿美元,预计2024年将达361.9亿美元,2030年将达到691.8亿美元,复合年增长率为11.37%。
血浆蛋白疗法由源自人类血浆的药物组成,血浆是血液的液体成分,含有负责人类健康所需的各种功能的必需蛋白质。这些治疗剂包括许多高度专业的治疗方法,旨在解决因特定血浆蛋白缺乏或功能障碍而引起的各种医疗状况。血浆蛋白疗法的市场开拓涉及这些临床用途蛋白的开发、生产和分销。自体免疫和神经系统疾病的盛行率不断增加,以及患者一生中定期输液和注射的需求不断增加,都促进了血浆蛋白治疗市场的成长。血浆蛋白疗法的快速取得和患者的负担能力也推动了市场的开拓。血浆蛋白疗法的副作用和有关血浆蛋白处理的严格规定限制了市场的成长。与血浆蛋白相关的研究和开发活动的增加表明血浆蛋白治疗市场的潜在成长机会。高效蛋白血浆提取/製造流程的开拓预计将推动市场成长。
主要市场统计 | |
---|---|
基准年[2023] | 325.5亿美元 |
预测年份 [2024] | 361.9亿美元 |
预测年份 [2030] | 691.8亿美元 |
复合年增长率(%) | 11.37% |
产品 增加使用 C1 酯酶抑制剂来控制和预防与 HAE 相关的肿胀发作
白蛋白是一种在肝臟中合成的蛋白质,负责维持血压和运输荷尔蒙、酵素和药物。在治疗病例中,白蛋白通常用作休克和烧伤的扩容剂,并用于治疗肝功能衰竭、肾病症候群和胃肠道蛋白质流失引起的低白蛋白血症。 C1-酯酶抑制剂是调节补体系统的蛋白质,补体系统是人体免疫反应的一部分。它主要用于治疗遗传性血管性水肿(HAE)。 HAE 是一种罕见的遗传性疾病,会导致身体各部位肿胀。凝血因子是血液凝固过程所必需的蛋白质。治疗性凝血因子可预防和控制A型血友病患者的出血,血友病是一种损害凝血的遗传性疾病。治疗包括替代缺乏或缺乏的凝血因子,并且可以预防性地给予以防止出血发作或根据需要来处理急性出血。超免疫球蛋白是一种血浆来源的免疫球蛋白,含有针对特定病原体和毒素的高浓度抗体。它用于预防和治疗乙型肝炎、狂犬病、破伤风和免疫力缺乏患者的某些感染疾病等疾病。免疫球蛋白(Igs)也称为抗体,用于治疗免疫力缺乏自体免疫疾病和发炎疾病、原发性和次发性免疫力缺乏以及某些感染疾病。静脉注射静脉注射(IVIg)和皮下静脉注射静脉注射(SCIg)是两种主要製剂形式,其选择很大程度取决于患者的偏好、耐受性和静脉注射的可及性。血浆蛋白产品的选择取决于具体的临床需求。白蛋白和凝血因子分别提供重要的血浆容量和凝血功能,后者俱有许多急性使用案例,例如创伤、手术和出血控制。 C1-酯酶抑制剂和超免疫球蛋白提供针对遗传性疾病和感染疾病的更有针对性的干预措施。免疫球蛋白最广泛地用作与自体免疫疾病和免疫力缺乏相关的多种疾病的治疗剂。基因治疗和现有治疗方法适应症的扩大等最新进展导致製造业由少数积极回应医疗需求的主要企业主导。
应用扩大血浆蛋白疗法在次发性于癌症和自体免疫疾病流行的免疫力缺乏疾病的应用
遗传性血管性水肿是一种罕见的遗传性疾病,会导致身体各部位突然、严重且不可预测的肿胀。 C1 酯酶抑制剂 (C1-INH) 浓缩物已用于治疗 HAE,最近,重组 C1-INH 疗法和激肽释放酶抑制剂已被用作按需治疗和预防。由于 HAE 发作会危及生命,因此非常需要这些治疗。特发性血小板减少紫斑症是一种自体免疫疾病,会导致血小板数量低,容易造成瘀伤和出血。静脉注射免疫静脉注射(IVIG)可以快速提高血小板计数,常用于治疗 ITP。原发性免疫力缺乏(PID) 是一组 300 多种疾病,患者身体部分免疫系统缺失或功能异常。患者通常需要终身治疗,通常需要更换免疫球蛋白 (Ig)。当免疫系统受到感染疾病、化疗或其他疾病等外部因素损害时,就会发生次发性免疫力缺乏(SID)。这四个应用领域的治疗需求差异很大,并且取决于每种疾病的严重程度和慢性性质。 HAE 和 ITP 通常需要快速反应治疗,而 PID 和 SID 则需要长期管理策略。
区域洞察
美洲血浆蛋白治疗市场由先进的医疗基础设施、较高的患者意识层级和主要行业参与者的存在推动,使美国成为全球主要市场之一。 FDA(美国食品药物管理局)的法规环境确保了严格的品质和安全标准。在南美洲,由于医疗保健支出增加和对血浆衍生疗法认识的提高,巴西和阿根廷正在成为血浆蛋白疗法的主要市场。由于医疗保健意识的提高、可支配收入的增加和人口老化,亚太地区(APAC)为血浆蛋白治疗市场提供了成长机会。中国和日本是该地区的重要市场,中国大力投资血浆采集和分离能力。欧洲拥有完善的医疗体系、高品质标准和优惠的报销政策。对免疫球蛋白的需求仍然强劲,欧洲国家是血浆产品的重要出口国。在波湾合作理事会(GCC) 国家,经济繁荣和医疗支出增加增加了对血浆蛋白治疗药物的需求。相反,儘管人们对血浆药物的兴趣不断增长,但非洲在医疗保健基础设施和获得治疗方面面临重大障碍。
FPNV定位矩阵
FPNV定位矩阵对于评估血浆蛋白治疗市场至关重要。我们检视与业务策略和产品满意度相关的关键指标,以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估,供应商被分为四个成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对血浆蛋白治疗市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献,以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外,该分析还提供了对该行业竞争特征的宝贵见解,包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略,从而在市场上获得竞争优势。
1. 市场渗透率:提供有关主要企业所服务的市场的全面资讯。
2. 市场开拓:我们深入研究利润丰厚的新兴市场,并分析其在成熟细分市场的渗透率。
3. 市场多元化:提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。
4.竞争评估与资讯:对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。
5. 产品开发与创新:提供对未来技术、研发活动和突破性产品开发的见解。
1.血浆蛋白治疗市场的市场规模与预测是多少?
2.血浆蛋白治疗市场预测期间需要考虑投资的产品、细分市场、应用和领域有哪些?
3.血浆蛋白治疗市场的技术趋势和法规结构是什么?
4.血浆蛋白治疗市场主要厂商的市场占有率是多少?
5. 进入血浆蛋白治疗市场的合适型态和策略性手段是什么?
[193 Pages Report] The Plasma Protein Therapeutics Market size was estimated at USD 32.55 billion in 2023 and expected to reach USD 36.19 billion in 2024, at a CAGR 11.37% to reach USD 69.18 billion by 2030.
Plasma protein therapeutics consist of medications derived from human plasma, the liquid component of the blood that contains essential proteins responsible for various functions necessary to human health. These therapeutics include an array of highly specialized treatments tailored to address a variety of medical conditions resulting from the absence or malfunctioning of specific plasma proteins. The market for plasma protein therapeutics includes developing, producing, and distributing these proteins for clinical use. Increased prevalence of autoimmune and neurological diseases, along with the increasing need for regular infusions or injections throughout the life of the patient, contribute to the growth of the plasma protein therapeutics market. Surging access and affordability of plasma protein therapies for patients also fuel the market development. The adverse effects of plasma protein therapeutics and strict regulations about handling plasma protein are restricting market growth. Increasing research and development activity related to the plasma protein presents a potential opportunity for growth in the plasma protein therapeutics market. The development of an efficient protein plasma extraction/manufacturing process is expected to create growth in the market.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 32.55 billion |
Estimated Year [2024] | USD 36.19 billion |
Forecast Year [2030] | USD 69.18 billion |
CAGR (%) | 11.37% |
Product: Rising usage of C1-esterase inhibitors to control and prevent the swelling attacks associated with HAE
Albumin, a protein synthesized by the liver, is responsible for maintaining oncotic blood pressure and transporting hormones, enzymes, and drugs. In therapeutics, albumins are often used as volume expanders in cases of shock or burns and to treat hypoalbuminemia due to liver failure, nephrotic syndrome, or gastrointestinal protein loss. C1-esterase inhibitors are proteins that regulate the complement system, which is part of the body's immune response. They are primarily used to treat hereditary angioedema (HAE), a rare genetic condition that causes swelling in various parts of the body. Coagulation factors are essential proteins in the blood clotting process. Therapeutic coagulation factors prevent and control bleeding in individuals with hemophilia A and B, which are genetic disorders that impair blood clotting. Treatments involve replacing defective or missing clotting factors, which can be administered prophylactically to prevent bleeding episodes or on-demand to manage acute bleeding. Hyperimmune globulins are plasma-derived immunoglobulins with high concentrations of antibodies targeting specific pathogens or toxins. They are used to prevent or treat diseases such as hepatitis B, rabies, tetanus, and certain types of infections in immunocompromised patients. Immunoglobulins (Ig), also known as antibodies, are used in treating a wide array of autoimmune and inflammatory diseases, primary and secondary immunodeficiencies, and certain infections. Intravenous immunoglobulin (IVIg) and subcutaneous immunoglobulin (SCIg) are the two main forms offered, with the choice largely depending on patient preference, tolerability, and vein accessibility. Specific clinical needs lead to the choice among plasma protein products. Albumins and coagulation factors provide critical volume and clotting functions, respectively, often with high-urgency use cases like trauma and surgery and bleeding control for the latter. C1-esterase inhibitors and hyperimmune globulins offer more targeted interventions, focusing on genetic and infectious diseases. Immunoglobulins have the broadest application range, treating various autoimmune and immunodeficiency-related conditions. The manufacturing landscape is dominated by a few key players who robustly respond to medical needs, emphasized by recent advancements such as gene therapies and expanded indications for existing treatments.
Application: Growing application of plasma protein therapeutics in the secondary immunodeficiency due to prevalence of cancer and autoimmune diseases
Hereditary angioedema is a rare genetic disorder indicated by sudden, severe, and unpredictable swelling in various parts of the body. Treatment for HAE involves C1 esterase inhibitor (C1-INH) concentrates and, more recently, recombinant C1-INH therapies and kallikrein inhibitors as on-demand treatment and prevention. The need for these therapies is high, given the life-threatening nature of HAE attacks. Idiopathic thrombocytopenic purpura is an autoimmune disease that results in a low platelet count, leading to easy bruising and bleeding. Intravenous immunoglobulin (IVIG) is generally used to treat ITP, as it can quickly elevate platelet counts. Primary Immunodeficiency Disorders (PID) represent a group of over 300 disorders where part of the body's immune system is missing or functions improperly. Patients typically require lifelong therapy, often with immunoglobulin (Ig) replacement. Secondary Immunodeficiency (SID) arises when an external source such as infection, chemotherapy, or another disease impairs the immune system. The therapeutic needs across these four application segments vary significantly, with demand being shaped by both the acuteness and the chronic nature of each condition. While HAE and ITP typically require rapid response treatments, PID and SID require longer-term management strategies.
Regional Insights
The plasma protein therapeutics market in the Americas is highly developing, with the United States being one of the major global markets, driven by advanced healthcare infrastructure, high patient awareness levels, and the presence of key industry players. The regulatory environment fostered by the FDA ensures stringent quality and safety standards. In South America, Brazil and Argentina are emerging as key markets for plasma protein therapeutics due to growing healthcare expenditures and awareness about plasma-derived therapies. The Asia-Pacific (APAC) region presents a growth opportunity for the plasma protein therapeutics market, attributed to rising healthcare awareness, increasing disposable incomes, and a growing aging population. China and Japan are significant markets in this region, with China investing heavily in plasma collection and fractionation capabilities. Europe has well-established healthcare systems, high-quality standards, and favorable reimbursement policies. The need for immunoglobulins remains robust, and European countries are significant exporters of plasma products. The Gulf Cooperation Council (GCC) countries demonstrate a rising need for plasma protein therapeutics due to economic prosperity and increased healthcare spending. Conversely, Africa faces considerable hurdles in healthcare infrastructure and treatment access, although the interest in plasma-derived medicinal products is growing.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Plasma Protein Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Plasma Protein Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Plasma Protein Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Access Biologicals LLC, ADMA Biologics, Inc., AmerisourceBergen Corporation, Baxter International Inc., Bio Products Laboratory Ltd., Bruker Corporation, China Biologic Products Holdings, Inc., CSL Limited, DiaPharma, Emergent BioSolutions, FFF Enterprises, Inc., GC Biopharma corp, Grifols, S.A., Hemarus Therapeutics Limited, KalVista Pharmaceuticals, Kamada Ltd., Kedrion S.p.A., Laboratory Corporation of America Holdings, LFB SA, Octapharma AG, Plasma Technologies, LLC, PlasmaGen BioSciences Pvt. Ltd., Reliance Industries Limited, Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific, Inc..
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Plasma Protein Therapeutics Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Plasma Protein Therapeutics Market?
3. What are the technology trends and regulatory frameworks in the Plasma Protein Therapeutics Market?
4. What is the market share of the leading vendors in the Plasma Protein Therapeutics Market?
5. Which modes and strategic moves are suitable for entering the Plasma Protein Therapeutics Market?